Updated Jul 16, 2026
RUBINSTEIN JULIE has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $13.37M.

Julie Rubinstein is an accomplished executive in the biotechnology industry, currently serving as the President and Chief Operating Officer (COO) of Adaptive Biotechnologies Corp. She has played a significant role in advancing the company's mission to harness the adaptive immune system to transform the diagnosis and treatment of disease. With extensive experience in leadership and operational roles, Rubinstein has contributed to the growth and strategic direction of the company.
| Role | President and COO |
|---|---|
| Notability | 75/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-29 | ADPT | Adaptive Biotechnologies Corp | S — Open-market sale | 19.0K | $14.23 | $271K |
| 2026-04-29 | ADPT | Adaptive Biotechnologies Corp | M — Option exercise | 14.7K | $8.46 | $124K |
| 2026-04-24 | ADPT | Adaptive Biotechnologies Corp | S — Open-market sale | 19.1K | $14.02 | $267K |
| 2026-04-24 | ADPT | Adaptive Biotechnologies Corp | M — Option exercise | 14.7K | $8.46 | $125K |
| 2026-04-24 | ADPT | Adaptive Biotechnologies Corp | S — Open-market sale | 19.1K | $13.74 | $262K |
| 2026-04-24 | ADPT | Adaptive Biotechnologies Corp | M — Option exercise | 14.7K | $8.46 | $125K |
| 2026-04-24 | ADPT | Adaptive Biotechnologies Corp | S — Open-market sale | 19.1K | $14.13 | $269K |
| 2026-04-24 | ADPT | Adaptive Biotechnologies Corp | M — Option exercise | 14.7K | $8.46 | $125K |
| 2026-04-21 | ADPT | Adaptive Biotechnologies Corp | S — Open-market sale | 30.9K | $14.66 | $454K |
| 2026-04-21 | ADPT | Adaptive Biotechnologies Corp | M — Option exercise | 11.9K | $12.14 | $144K |
| 2026-04-21 | ADPT | Adaptive Biotechnologies Corp | M — Option exercise | 14.7K | $8.46 | $125K |
| 2026-04-21 | ADPT | Adaptive Biotechnologies Corp | S — Open-market sale | 19.1K | $14.55 | $277K |
| 2026-04-21 | ADPT | Adaptive Biotechnologies Corp | M — Option exercise | 14.7K | $8.46 | $125K |
| 2026-04-21 | ADPT | Adaptive Biotechnologies Corp | S — Open-market sale | 19.1K | $14.57 | $278K |
| 2026-04-21 | ADPT | Adaptive Biotechnologies Corp | M — Option exercise | 14.7K | $8.46 | $125K |
| 2026-04-16 | ADPT | Adaptive Biotechnologies Corp | S — Open-market sale | 19.1K | $14.18 | $270K |
| 2026-04-16 | ADPT | Adaptive Biotechnologies Corp | M — Option exercise | 14.7K | $8.46 | $125K |
| 2026-04-16 | ADPT | Adaptive Biotechnologies Corp | S — Open-market sale | 19.1K | $14.61 | $278K |
| 2026-04-16 | ADPT | Adaptive Biotechnologies Corp | M — Option exercise | 14.7K | $8.46 | $125K |
| 2026-04-16 | ADPT | Adaptive Biotechnologies Corp | S — Open-market sale | 19.1K | $14.56 | $278K |
Julie Rubinstein is an accomplished executive in the biotechnology industry, currently serving as the President and Chief Operating Officer (COO) of Adaptive Biotechnologies Corp. She has played a significant role in advancing the company's mission to harness the adaptive immune system to transform the diagnosis and treatment of disease. With extensive experience in leadership …
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 47 open-market sales ($13.37M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live RUBINSTEIN JULIE profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.